Vaxart Inc. (VXRT): Price and Financial Metrics


Vaxart Inc. (VXRT): $1.08

-0.01 (-0.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VXRT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VXRT POWR Grades

  • Value is the dimension where VXRT ranks best; there it ranks ahead of 34.73% of US stocks.
  • The strongest trend for VXRT is in Growth, which has been heading up over the past 177 days.
  • VXRT ranks lowest in Stability; there it ranks in the 2nd percentile.

VXRT Stock Summary

  • With a price/sales ratio of 908.01, VAXART INC has a higher such ratio than 99.56% of stocks in our set.
  • As for revenue growth, note that VXRT's revenue has grown -86.46% over the past 12 months; that beats the revenue growth of just 1.52% of US companies in our set.
  • In terms of volatility of its share price, VXRT is more volatile than 93.6% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to VAXART INC are AGIO, PLRX, TSVT, MRUS, and EDIT.
  • VXRT's SEC filings can be seen here. And to visit VAXART INC's official web site, go to vaxart.com.

VXRT Valuation Summary

  • In comparison to the median Healthcare stock, VXRT's price/sales ratio is 17213.73% higher, now standing at 883.
  • VXRT's price/sales ratio has moved up 882 over the prior 243 months.

Below are key valuation metrics over time for VXRT.

Stock Date P/S P/B P/E EV/EBIT
VXRT 2023-01-30 883.0 1.1 -1.3 -1.1
VXRT 2023-01-27 916.4 1.2 -1.4 -1.1
VXRT 2023-01-26 891.2 1.2 -1.4 -1.1
VXRT 2023-01-25 916.4 1.2 -1.4 -1.1
VXRT 2023-01-24 891.2 1.2 -1.4 -1.1
VXRT 2023-01-23 908.2 1.2 -1.4 -1.1

VXRT Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at -267.33%.
  • Its 4 year cash and equivalents growth rate is now at 153.04%.
  • The 2 year price growth rate now stands at 7.85%.
Over the past 15 months, VXRT's revenue has gone down $1,080,000.

The table below shows VXRT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0.159 -81.441 -104.604
2022-06-30 0.359 -81.093 -92.878
2022-03-31 0.471 -68.353 -79.564
2021-12-31 0.892 -59.832 -70.47
2021-09-30 1.174 -54.784 -63.567
2021-06-30 1.239 -49.772 -54.069

VXRT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VXRT has a Quality Grade of D, ranking ahead of 8.43% of graded US stocks.
  • VXRT's asset turnover comes in at 0.007 -- ranking 401st of 680 Pharmaceutical Products stocks.
  • ABEO, BCDA, and PCRX are the stocks whose asset turnover ratios are most correlated with VXRT.

The table below shows VXRT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.007 1 -2.885
2021-03-31 0.011 1 -7.113
2020-12-31 0.038 1 81.691
2020-09-30 0.099 1 12.466
2020-06-30 0.159 1 19.968
2020-03-31 0.174 1 -81.273

VXRT Price Target

For more insight on analysts targets of VXRT, see our VXRT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.50 Average Broker Recommendation 1.5 (Moderate Buy)

VXRT Stock Price Chart Interactive Chart >

Price chart for VXRT

VXRT Price/Volume Stats

Current price $1.08 52-week high $5.43
Prev. close $1.08 52-week low $0.73
Day low $1.06 Volume 966,628
Day high $1.11 Avg. volume 1,924,467
50-day MA $1.07 Dividend yield N/A
200-day MA $2.52 Market Cap 141.09M

Vaxart Inc. (VXRT) Company Bio


Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.


VXRT Latest News Stream


Event/Time News Detail
Loading, please wait...

VXRT Latest Social Stream


Loading social stream, please wait...

View Full VXRT Social Stream

Latest VXRT News From Around the Web

Below are the latest news stories about VAXART INC that investors may wish to consider to help them evaluate VXRT as an investment opportunity.

Covid Isn’t Going Away. New Drugs Are Coming.

Drug makers are preparing everything from a vaccine that comes as a pill to a better version of Paxlovid.

Yahoo | January 18, 2023

Profound Medical (PROF) Surges 5.1%: Is This an Indication of Further Gains?

Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Yahoo | January 9, 2023

Vaxart Names Phillip Lee as Chief Financial Officer

Mr. Lee brings almost 15 years of experience in strategy, M&A and partnering on more than $20 billion in transactions SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) announced today that it has appointed Phillip Lee as its Chief Financial Officer (CFO), effective immediately. “We are excited to have a CFO with Phillip’s experience in corporate finance and strategy join our team,” said Andrei Floroiu, Vaxart’s Chief Executive Officer. “He arrives at an i

Yahoo | December 19, 2022

Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers

Funding and support provided by Bill & Melinda Gates Foundation Study will focus on determining the ability of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to young infants SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced it will commence a new study of Vaxart’s oral pill norovirus vaccine candidate focused on protecting breastfeeding mothers and their infants. The study will receive significant funding

Yahoo | December 1, 2022

Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine & Immunotherapy Congress West Coast 2022 in San Diego on Tuesday, November 29, 2022 at 1:50 p.m. PT / 4:50 p.m. ET. Dr. Tucker will provide an overview of Vaxart’s Phase II trial for its oral pill COVID-19 vaccine candidate. Vaxart recently announced positive top-line Phase II clinical study result

Yahoo | November 22, 2022

Read More 'VXRT' Stories Here

VXRT Price Returns

1-mo 10.85%
3-mo -22.30%
6-mo -75.78%
1-year -77.50%
3-year -2.70%
5-year -85.12%
YTD 12.39%
2022 -84.67%
2021 9.81%
2020 1,529.10%
2019 -81.36%
2018 -70.02%

Continue Researching VXRT

Here are a few links from around the web to help you further your research on Vaxart Inc's stock as an investment opportunity:

Vaxart Inc (VXRT) Stock Price | Nasdaq
Vaxart Inc (VXRT) Stock Quote, History and News - Yahoo Finance
Vaxart Inc (VXRT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7926 seconds.